Stockscreener 앱 받기
254.47
0.07%
0.19
시간 외 거래:
252.55
-1.92
-0.75%
전일 마감가:
$254.28
열려 있는:
$253.66
하루 거래량:
419.81K
Relative Volume:
0.51
시가총액:
$16.52B
수익:
$4.44B
순이익/손실:
$29.49M
주가수익비율:
-13,829.89
EPS:
-0.0184
순현금흐름:
$1.19B
1주 성능:
+2.46%
1개월 성능:
+0.24%
6개월 성능:
+46.39%
1년 성능:
+106.70%
1일 변동 폭
$250.44
$254.70
1주일 범위
$245.76
$256.92
52주 변동 폭
$122.50
$265.05
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
명칭
Jazz Pharmaceuticals Plc
전화
353-1-634-7800
주소
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
254.47 | 16.14B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 재개 | Raymond James | Outperform |
| 2026-02-27 | 개시 | Barclays | Overweight |
| 2025-11-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-15 | 개시 | Deutsche Bank | Buy |
| 2025-03-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-26 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 개시 | Goldman | Buy |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-11-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-09-29 | 개시 | Raymond James | Mkt Perform |
| 2023-06-12 | 재개 | Wells Fargo | Equal Weight |
| 2022-12-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Buy |
| 2022-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-11-19 | 재개 | Goldman | Buy |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-10-05 | 개시 | Citigroup | Buy |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-05-19 | 재개 | JP Morgan | Overweight |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | 개시 | Jefferies | Buy |
| 2020-03-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Neutral |
| 2019-08-21 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Peer Perform |
| 2018-11-08 | 재확인 | B. Riley FBR | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | 재확인 | H.C. Wainwright | Neutral |
| 2018-03-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
Advisors Preferred LLC Acquires New Shares in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals (JAZZ) As HER2 Pipeline Progress Fuels An Undervalued Narrative - simplywall.st
Great Lakes Advisors LLC Invests $8.15 Million in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Announces $820 Million Acquisition of Actio Biosciences - Global Legal Chronicle
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jessica Merrill: Mid-Cap Biopharma's $1B-Plus Deal Surge Could Spawn the Next Amgen - finance.biggo.com
Jazz Pharmaceuticals (JAZZ) Stock Analysis: A Glimpse Into The 14.86% Potential Upside - DirectorsTalk Interviews
Jazz Pharmaceuticals PLC at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
Understanding HER2 Expression in Gastroesophageal AdenocarcinomaJazz Pharmaceuticals - Oncodaily
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Jazz Pharmaceuticals plc: Target Price Consensus and Analysts Recommendations | JAZZ | IE00B4Q5ZN47 - marketscreener.com
Irish Jazz Pharmaceuticals acquires American Actio for $1.32 billion - AKM.RU
Jazz Pharmaceuticals (JAZZ) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed - simplywall.st
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout (JAZZ) - Seeking Alpha
Wedge Capital Management L L P NC Sells 33,467 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call - Yahoo Finance
JAZZ Maintained by Morgan Stanley -- Price Target Raised to $283 - GuruFocus
Jazz Pharmaceuticals (JAZZ) Acquires Actio Biosciences for $820 Million - GuruFocus
Jazz Pharmaceuticals' Actio Acquisition 'Makes Sense,' Has Good Synergy, RBC Says - marketscreener.com
Morgan Stanley Adjusts Jazz Pharmaceuticals PT to $283 From $280, Maintains Overweight Rating - marketscreener.com
Jazz Pharmaceuticals buys Actio for up to $1.3bn - BioXconomy
Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Q2 2026 Earnings Call Transcript - The Globe and Mail
Jazz Pharmaceuticals plc (JAZZ) stock price, news, quote and history - Yahoo Finance Singapore
Jazz Pharmaceuticals to Acquire Actio Biosciences in Merger - TipRanks
Jazz Pharmaceuticals (JAZZ) plans $820M Actio Biosciences deal plus $500M milestones - Stock Titan
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M - Investing.com India
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Solid Earnings Are Supported By Other Strong Factors - 富途牛牛
Jazz Pharma Buying Actio In Up To $1.32B Epilepsy Push - Law360
Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal - BioPharma Dive
Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio - reuters.com
Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline - BioSpace
JAZZ Looks 70.7% Overvalued on GF Value™ Amid $820M Actio Biosci - GuruFocus
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects - Yahoo Finance
Jazz Pharmaceuticals to Acquire Actio Biosciences in Deal Worth Up to $1.32 Billion - citybiz
JAZZ Looks 68.7% Overvalued on GF Value™ After Actio Biosciences Acquisition - GuruFocus
Jazz Pharmaceuticals to Acquire Rare Epilepsy Specialist Actio - TipRanks
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M By Investing.com - Investing.com Australia
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, gaining a new epilepsy drug ABS-1230. - Pluang
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio - PR Newswire
Royal Bank of Canada Has $8.56 Million Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals (JAZZ): Investor Outlook on a Biotech Powerhouse with a 9.51% Upside Potential - DirectorsTalk Interviews
Jazz Pharmaceuticals PLC (JAZZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jazz Pharmaceuticals plc 2026 Q2ResultsEarnings Call Presentation (NASDAQ:JAZZ) 2026-08-07 - Seeking Alpha
Jazz Pharmaceuticals plc SEC Filing (Aug 7, 2026) - Stock Titan
Jazz Pharmaceuticals plc (JAZZ) News, Articles, Events & Latest Updates - Stocktwits
JAZZ vs. TECH: Which Stock Is the Better Value Option? - Yahoo Finance
FMR LLC and Abigail Johnson disclose 7.4% Jazz Pharmaceuticals (JAZZ) ownership - Stock Titan
Jazz Pharmaceuticals (JAZZ) Director Bruce Cozadd Sells 6,000 Sh - GuruFocus
Jazz Pharmaceuticals Plc Just Missed EPS By 13%: Here's What Analysts Think Will Happen Next - Moomoo
What Does Jazz Pharmaceuticals (JAZZ) Raised Guidance Mean With FDA Decisions Ahead? - Yahoo Finance
Jazz Pharmaceuticals Plc (JAZZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
3.22%
자본화:
|
볼륨(24시간):